DiaMedica Therapeutics (DMAC) Change in Accured Expenses (2018 - 2026)

DiaMedica Therapeutics' Change in Accured Expenses history runs 9 years deep, the most recent figure standing at -$1.2 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 6.46% year-over-year to -$1.2 million in Q1 2026; TTM through Mar 2026 was -$807000.0, a 169.87% decrease from a year earlier, with the FY2025 full-year figure at -$892000.0, down 135.84% from the prior year.
• Change in Accured Expenses declined to -$1.2 million in Q1 2026 per DMAC's latest filing, from $282000.0 in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $1.3 million in Q4 2024 and bottomed at -$1.3 million in Q1 2025.
• The 5-year median for Change in Accured Expenses is $38000.0 (2023), against an average of $63588.2.
• Across the five-year window, Change in Accured Expenses soared 936.84% in 2024 and tumbled 7021.05% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $737000.0 in 2022, then slipped by 28.09% to $530000.0 in 2023, then soared by 145.47% to $1.3 million in 2024, then sank by 78.32% to $282000.0 in 2025, then plunged by 536.17% to -$1.2 million in 2026.
• Per Business Quant, the three latest DMAC Change in Accured Expenses figures stand at -$1.2 million (Q1 2026), $282000.0 (Q4 2025), and $469000.0 (Q3 2025).